Last reviewed · How we verify
Placebo for isoniazid (INH)
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in isoniazid efficacy and safety trials for tuberculosis.
At a glance
| Generic name | Placebo for isoniazid (INH) |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Placebos are inert substances used as controls in clinical trials to establish the efficacy of active drugs by comparison. Any observed effects in placebo groups are attributed to the placebo effect—psychological and physiological responses to the expectation of treatment rather than the drug itself. In this case, it serves as a control comparator in isoniazid (INH) studies for tuberculosis.
Approved indications
- Control arm in isoniazid efficacy and safety trials for tuberculosis
Common side effects
Key clinical trials
- Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis (PHASE3)
- Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis (PHASE3)
- Adjunctive Doxycycline for Central Nervous System Tuberculosis (PHASE2)
- Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease (PHASE3)
- Observation Study on the Efficacy of Yiqi Gubiao Pill in the Treatment of Chronic Obstructive Pulmonary Disease Secondary to Active Pulmonary Tuberculosis (EARLY_PHASE1)
- Safety of Administering Isoniazid to SLE Patients to Prevent TB (PHASE2, PHASE3)
- Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis (PHASE3)
- Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: